FOX Translator
No data currently available.
No data currently available.
In the wide and varied family of the thousands and thousands of funds out there, the exchange-traded fund is one of the more consumer-friendly ones.
Unlike mutual funds, exchange-traded funds, or ETFs, behave more like stocks. You can buy
into an ETF at any time, and sell it whenever you feel like it. And like a stock, an ETF's value can rise and fall--depending
on what the ETF is invested in.What do ETFs invest in? Well, they're typically linked to an index like the Dow Jones Industrial
Average or the S&P 500. So, if you had an ETF that trades the same companies that make up the Dow or the S&P, it will
rise and fall in value pretty much the same amount as the Dow or S&P.
You can also buy ETFs that invest in other
types of products, like bonds, currencies, gold or other commodities. The ETF market has grown considerably in the past few
years, so there is no shortage of ETFs to invest in.
Home / Markets / Industries / Health Care
Wednesday, May 14, 2008
Phase II Clinical Trial of Sinobiomed's Malaria Candidate Vaccine to Start in Q3
Comtex
SHANGHAI, CHINA, May 14, 2008 (MARKET WIRE via COMTEX News Network) ----Sinobiomed Inc. ("Sinobiomed", or the "Company") (OTCBB: SOBM) is pleased to announce that it is launching the Phase II Clinical Trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in Q3 2008.
Sinobiomed will conduct the trial in collaboration with Mahidol University in Bangkok, Thailand. The study site is located in Thailand's Ratchaburi Province, approximately 200 km from Bangkok near the Myanmar border. The university's Faculty of Tropical Medicine has extensive experiences in conducting vaccine trials. Since 1998, the faculty has participated in field trials for another malaria vaccine candidate in its Vaccine Trial Center (VTC) in Ratchaburi Province. Currently the VTC is sponsoring Phase II trials for an HIV vaccine and a dengue fever vaccine. Preparations for the Phase II trial of PfCP2.9 are now underway.
The Phase I Clinical Trial showed that PfCP2.9 had strong ability to generate an immune response (immunogenicity) with only mild adverse effects, and worked out the optimal dose levels and vaccination schedule required for the next trial. In January 2008, Sinobiomed was approved to receive grants from government funding of RMB 9 million (US$1.24 million) to undertake the Phase II clinical trial of its recombinant malaria vaccine in epidemic areas.
In 2004, Shanghai Wanxing received RMB 3 million (US $360,000) from the Ministry of Science and Technology to support the Phase I Clinical Trial of the vaccine. Sinobiomed has exclusive usage rights to the PfCP2.9 vaccine, which was developed by SMMU. PfCP2.9 has been granted Chinese, U.S., E.U. and Australian patents.
ABOUT SINOBIOMED INC.
Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.
FORWARD LOOKING STATEMENTS: This news release may include "forward-looking
statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contacts: Sinobiomed Inc. Investor Relations (718) 502-8801 or Toll Free: 1-866-588-0829 Email: info@sinobiomed.com Website: www.sinobiomed.com
SOURCE: Sinobiomed Inc.
mailto:info@sinobiomed.com http://www.sinobiomed.com
Copyright 2008 Market Wire, All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
